BACKGROUND: Symptoms in keeping with autonomic dysfunction are commonly described by primary Sjögrens syndrome patients (pSS); whether objective abnormalities of autonomic function occur is unclear. This study set out to explore dynamic cardiovascular autonomic responses in pSS and their relationship with symptoms and quality of life. METHODS: Twenty-one people from the UK pSS registry, 21 community controls and 21 patients with the autoimmune liver disease primary biliary cirrhosis (PBC) (matched case-wise for age and sex) attended for assessment of autonomic responses to orthostasis and Valsalva manoeuvre (VM). pSS patients also completed EULAR Sjögrens Syndrome patient-reported index (ESSPRI), EULAR Sjögren's syndrome disease activity index (ESSDAI), fatigue impact scale and EURO-QOL 5-dimension (EQ-5D). RESULTS: Compared with controls, pSS patients had significantly lower baseline systolic blood pressure (SBP) (114 ± 13 vs. 127 ± 20; P = 0.02), which dropped to a significantly lower value (98 ± 22 vs. 119 ± 24, P = 0.009). When area under the curve (AUC) was calculated for when the SBP was below baseline this was significantly greater in pSS compared to both control groups (pSS vs. control vs. PBC: 153 ± 236 vs. 92 ± 85 vs. 1.2 ± 0.3, P = 0.005). Peak phase IV SBP during the VM was significantly lower in pSS (P = 0.007) indicating early sympathetic failure. Increased heart rate associated with fatigue (P = 0.02; r(2) = 0.2) and EQ-5D. A shift in sympathetic-vagal balance associated with overall symptom burden (ESSPRI) (P = 0.04, r(2) = 0.3) and EULAR sicca score (P = 0.016; r(2) = 0.3), the latter also correlated with baroreceptor effectiveness (P = 0.03; r(2) = 0.2) and diastolic blood pressure variability (P = 0.003; r(2) = 0.4). CONCLUSION: pSS patients have impaired blood pressure response to standing. Dysautonomia correlates with PSS-associated symptoms and quality of life.
BACKGROUND: Symptoms in keeping with autonomic dysfunction are commonly described by primary Sjögrens syndrome patients (pSS); whether objective abnormalities of autonomic function occur is unclear. This study set out to explore dynamic cardiovascular autonomic responses in pSS and their relationship with symptoms and quality of life. METHODS: Twenty-one people from the UK pSS registry, 21 community controls and 21 patients with the autoimmune liver disease primary biliary cirrhosis (PBC) (matched case-wise for age and sex) attended for assessment of autonomic responses to orthostasis and Valsalva manoeuvre (VM). pSSpatients also completed EULAR Sjögrens Syndrome patient-reported index (ESSPRI), EULAR Sjögren's syndrome disease activity index (ESSDAI), fatigue impact scale and EURO-QOL 5-dimension (EQ-5D). RESULTS: Compared with controls, pSSpatients had significantly lower baseline systolic blood pressure (SBP) (114 ± 13 vs. 127 ± 20; P = 0.02), which dropped to a significantly lower value (98 ± 22 vs. 119 ± 24, P = 0.009). When area under the curve (AUC) was calculated for when the SBP was below baseline this was significantly greater in pSS compared to both control groups (pSS vs. control vs. PBC: 153 ± 236 vs. 92 ± 85 vs. 1.2 ± 0.3, P = 0.005). Peak phase IV SBP during the VM was significantly lower in pSS (P = 0.007) indicating early sympathetic failure. Increased heart rate associated with fatigue (P = 0.02; r(2) = 0.2) and EQ-5D. A shift in sympathetic-vagal balance associated with overall symptom burden (ESSPRI) (P = 0.04, r(2) = 0.3) and EULAR sicca score (P = 0.016; r(2) = 0.3), the latter also correlated with baroreceptor effectiveness (P = 0.03; r(2) = 0.2) and diastolic blood pressure variability (P = 0.003; r(2) = 0.4). CONCLUSION:pSSpatients have impaired blood pressure response to standing. Dysautonomia correlates with PSS-associated symptoms and quality of life.
Authors: R Sakakibara; S Hirano; M Asahina; S Sawai; Y Nemoto; A Hiraga; T Uchiyama; T Hattori Journal: Eur J Neurol Date: 2004-09 Impact factor: 6.089
Authors: László Kovács; Dóra Paprika; Róbert Tákacs; Attila Kardos; Tamás T Várkonyi; Csaba Lengyel; Attila Kovács; László Rudas; Gyula Pokorny Journal: Rheumatology (Oxford) Date: 2003-08-29 Impact factor: 7.580
Authors: Jennifer Goldblatt; Philip J S Taylor; Toby Lipman; Martin I Prince; Anna Baragiotta; Margaret F Bassendine; Oliver F W James; David E J Jones Journal: Gastroenterology Date: 2002-05 Impact factor: 22.682
Authors: L Kovács; M Papós; R Takács; R Róka; Z Csenke; A Kovács; T Várkonyi; L Pajor; L Pávics; G Pokorny Journal: Clin Exp Rheumatol Date: 2003 Nov-Dec Impact factor: 4.473
Authors: Richard Imrich; Ilias Alevizos; Lolita Bebris; David S Goldstein; Courtney S Holmes; Gabor G Illei; Nikolay P Nikolov Journal: Arthritis Rheumatol Date: 2015-05 Impact factor: 10.995
Authors: Jessica A Inskip; Henrike Rianne J C Ravensbergen; Inderjeet S Sahota; Christine Zawadzki; Lowell T McPhail; Jaimie F Borisoff; Victoria E Claydon Journal: PLoS One Date: 2017-06-30 Impact factor: 3.240